NDC 22840-1028-02: House Fly Musca domestica 40000 [PNU]/mL Solution, 10 mL Vial
This is a package of 10 mL of House Fly Musca domestica 40000 [PNU]/mL Solution from Greer Laboratories, Inc., first listed with the FDA Sep 1981 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 22840-1028-2 alone.
- Record
- FDA NDC Directory package listing · Non-standardized allergenic
- Code segments
- 22840 labeler · 1028 product · 2 package
- Package marketed since
- Sep 15, 1981
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 2284010282 0
- FDA record last changed
- Oct 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 22840-1028-02 You're viewing this Main listing | 10 mL in 1 VIAL, MULTI-DOSE | 1981-09-15 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| House Fly 40000 [PNU]/mLthis 22840-1028-02 | Greer | 10 ml | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 339NCG44TV
Phenol is a chemical compound derived from coal tar or petroleum. It serves as a preservative and antimicrobial agent in medicines, helping prevent bacterial and fungal growth to keep the product stable and safe during storage.
-
UNII 8MDF5V39QO
A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Greer Laboratories, Inc. labeler code 22840
- Mosquito Aedes taeniorhynchus .05 g/mL Solution NDC 22840-1022-2
- Fire Ant Solenopsis invicta .1 g/mL Solution NDC 22840-1023-2
- American Cockroach Periplaneta americana .1 g/mL Solution NDC 22840-1024-2
- German Cockroach Blattella germanica .1 g/mL Solution NDC 22840-1025-2
- House Fly Musca domestica .001 g/mL Solution NDC 22840-1026-1
- House Fly Musca domestica 20000 [PNU]/mL Solution NDC 22840-1027-2
- Mosquito Aedes taeniorhynchus 20000 [PNU]/mL Solution NDC 22840-1029-2
- Mosquito Aedes taeniorhynchus 10000 [PNU]/mL Solution NDC 22840-1030-2
- Cattle Epithelia Bos taurus .1 g/mL Solution NDC 22840-1100-2
- Cattle Epithelia Bos taurus 20000 [PNU]/mL Solution NDC 22840-1101-2
- Cattle Epithelia Bos taurus .05 g/mL Solution NDC 22840-1102-2
- Cattle Epithelia Bos taurus .001 g/mL Solution NDC 22840-1103-1
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
🚨 Boxed Warning ▾
FULL PRESCRIBING INFORMATION WARNING: SEVERE ALLERGIC REACTIONS Non-Standardized Allergenic Extracts can cause severe life-threatening systemic reactions, including anaphylaxis. (5.1) Do not administer these products to patients with severe, unstable, or uncontrolled asthma. (4) Observe patients in the office for at least 30 minutes following treatment.
Emergency measures and personnel trained in their use must be available immediately in the event of a life-threatening reaction. (5.1) Patients with extreme sensitivity to these products, those on an accelerated immunotherapy build-up schedule, those switching to another allergenic lot, those receiving high doses of Non-Standardized Allergenic Extracts, or those also exposed to similar allergens may be at increased risk of a severe allergic reaction. (5.1) These products may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
(5.1) These products may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. (5.2)
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Non-Standardized Allergenic Extracts are indicated for: Skin test diagnosis of patients with a clinical history of allergies to one or more of the specific non-standardized allergens. Immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by appropriate positive skin tests or by in vitro testing for allergen-specific IgE antibodies. Food extracts have not been proven safe or effective in allergen immunotherapy.
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION For percutaneous, intradermal or subcutaneous use only. The extracts are diluted with sterile diluents when used for intradermal testing or subcutaneous immunotherapy. For percutaneous testing, the extracts are diluted with sterile diluents in patients expected to be at greater risk for systemic allergic reaction. Dosages vary by mode of administration and by individual response.
2.1Preparation for Administration Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard solution if either of these conditions exist. The extracts are diluted with sterile diluents when used for percutaneous and intradermal testing, or for subcutaneous immunotherapy.
Extracts labeled “For Diagnostic Use Only” are intended for percutaneous and intradermal testing only. These extracts have not been shown by adequate data to be safe and effective for therapeutic use. The extracts labeled For Diagnostic Use Only are the foods Barley, Coffee, Oat, Pineapple, Rye, Spinach, Wheat, the insects Flea, House Fly, Mosquito, and the plant and plant parts Cottonseed and Flax.
Undiluted 50% glycerin stock concentrate is used for percutaneous testing. To prepare 10-fold dilutions for percutaneous testing in patients suspected to be at greater risk for systemic allergic reaction, start with the stock concentrate. Proceed as shown in Table 1.
The 10-fold dilution series uses 0.5 milliliters of concentrate added to 4.5 milliliters of sterile 50% glycerin diluent. Subsequent dilutions are made in a similar manner. To prepare 10-fold dilutions for intradermal testing and immunotherapy, start with a 1:10 weight/volume, 1:20 weight/volume, or up to a 40,000 PNU/milliliter stock concentrate.
Proceed as shown in Table 1. The 10-fold dilution series uses 0.5 milliliter of concentrate added to 4.5 milliliters of sterile diluent (glycerin-free diluents for intradermal testing, glycerin-free or 10% glycerin-saline diluents for immunotherapy). Subsequent dilutions are made in a similar manner.
Table: 10-fold Dilution Series* Dilution Extract Milliliters of Diluent Dilution of Strength (w/v) Dilution of Strength (w/v) Dilution of Strength (PNU/milliliter) 0 Concentrate 1:10 1:20 20,000 1 0.5 mL Concentrate 4.5 1:100 1:200 2,000 2 0.5 mL Dilution 1 4.5 1:1,000 1:2,000 200 3 0.5 mL Dilution 2 4.5 1:10,000 1:20,000 20 4 0.5 mL Dilution 3 4.5 1:100,000 1:200,000 2 5 0.5 mL Dilution 4 4.5 1:1,000,000 1:2,000,000 0.2 6 0.5 mL Dilution 5 4.5 1:10,000,000 1:20,000,000 0.02 *There is no direct potency correlation across the table between PNU/milliliter and w/v.
Undiluted 50% glycerin stock concentrate is used for percutaneous testing. To prepare 5-fold dilutions for percutaneous testing in patients suspected to be at greater risk for systemic allergic reaction, start with the stock concentrate. Proceed as shown in Table 2.
The 5-fold dilution series uses 1 milliliter of concentrate added to 4 milliliters of sterile 50% glycerin diluent. Subsequent dilutions are made in a similar manner. To prepare 5-fold dilutions for intradermal testing or immunotherapy, start with a 1:10 weight/volume, 1:20 weight/volume, or up to a 40,000 PNU/milliliter stock concentrate.
Proceed as shown in Table 2. The 5-fold dilution series uses 1 milliliter of concentrate added to 4 milliliters of sterile diluent (glycerin-free diluents for intradermal testing, glycerin-free or 10% glycerin-saline diluents for immunotherapy). Subsequent dilutions are made in a similar manner.
Table 2: 5-fold Dilution Series* Dilution Extract Milliliters of Diluent Dilution of Strength (w/v) Dilution of Strength (w/v) Dilution of Strength (PNU/milliliter) 0 Concentrate 1:10 1:20 20,000 1 1 mL Concentrate 4 1:50 1:100 4,000 2 1 mL Dilution 1 4 1:250 1:500 800 3 1 mL Dilution 2 4 1:1,250 1:2,500 160 4 1 mL Dilution 3 4 1:6,250 1:12,500 32 5 1 mL Dilution 4 4 1:31,250 1:62,500 6.4 6 1 mL Dilution… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Non-Standardized Allergenic Extracts are labeled in weight/volume and/or protein nitrogen units (PNU)/milliliter (a measure of total protein), and are supplied as sterile aqueous stock concentrates at up to 1:10 weight/volume or 40,000 PNU/milliliter, or 50% glycerin stock concentrates at up to 1:20 weight/volume.
⛔ Contraindications ▾
4 CONTRAINDICATIONS Non-Standardized Allergenic Extracts are contraindicated in patients with: Severe, unstable or uncontrolled asthma History of any severe systemic or local allergic reaction to an allergen extract
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS
5.1Serious Systemic Adverse Reactions Serious systemic adverse reactions have occurred following the administration of other allergenic extracts and may occur in individuals following the administration of Non-Standardized Allergenic Extracts in the following situations: Extreme sensitivity to the specific allergen(s) Receipt of an accelerated immunotherapy build-up schedule (e.g., “rush” immunotherapy) Receipt of high doses of allergenic extracts or concomitant exposure to similar environmental allergens Change from one allergenic extract lot to another allergenic extract lot High-risk patients have had fatal reactions.
Consider using more dilute preparations in patients suspected to be at greater risk of systemic allergic reaction [see Dosage and Administration (2.1)]. Administer Non-Standardized Allergenic Extracts in a healthcare setting under the supervision of a physician prepared to manage a severe systemic or a severe local allergic reaction.Observe patients in the office for at least 30 minutes following administration. 1
5.2Epinephrine Non-Standardized Allergenic Extracts may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute), unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension. These products may not be suitable for patients who are taking medications that can potentiate or inhibit the effect of epinephrine.
These medications include: Βeta-adrenergic blockers : Patients taking beta-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis. Specifically, beta-adrenergic blockers antagonize the cardiostimulating and bronchodilating effects of epinephrine. Alpha-adrenergic blockers, ergot alkaloids : Patients taking alpha-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis.
Specifically, alpha-adrenergic blockers antagonize the vasoconstricting and hypertensive effects of epinephrine. Similarly, ergot alkaloids may reverse the pressor effects of epinephrine. Tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and certain antihistamines : The adverse effects of epinephrine may be potentiated in patients taking tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and the antihistamines chlorpheniramine, and diphenhydramine.
Cardiac glycosides, diuretics : Patients who receive epinephrine while taking cardiac glycosides or diuretics should be observed carefully for the development of cardiac arrhythmias.
5.3Anaphylaxis Following False Negative Food Allergen Skin Test Results False negative skin test results associated with anaphylaxis from subsequent exposure to the allergen have been reported during postmarketing diagnostic use of some food allergenic extracts. Based on the patient’s clinical history and index of suspicion, healthcare providers should consider confirming negative skin testing with serologic testing by measuring specific serum IgE or with a medically-supervised oral food challenge.
5.4Cross-Reactions and Dose Sensitivity When determining the final dose of an allergen mixture for immunotherapy, consider cross-reactivity among component extracts. Determine the initial dilution of allergenic extract, starting dose, and progression of dosage based on the patient’s history and results of skin tests 2 [see Dosage and Administration (2.1)]. Strongly positive skin tests can be indicators for potential adverse reactions.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The most common adverse reactions, occurring in 26 to 82% of all patients who receive subcutaneous immunotherapy are local adverse reactions at the injection site (e.g., erythema, itching, swelling, tenderness, pain). 1 Systemic adverse reactions, occurring in < 7% of patients who receive subcutaneous immunotherapy, 3 include generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, and hypotension. These adverse reactions can be fatal.
1 The allergenic extracts labeled “For Diagnostic Use Only” that contain sodium formaldehyde sulfoxylate (SFS) can cause slight discoloration of the skin at the site of administration. This discoloration can remain for extended amounts of time.
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS
7.1Antihistamines Do not perform skin testing with allergenic extracts within 3 to 10 days of use of first-generation H1-histamine receptor blockers (e.g., clemastine, diphenhydramine) and second-generation antihistamines (e.g., loratadine, cetirizine). These products suppress histamine skin test reactions and could mask a positive response. 2
7.2Topical Corticosteroids and Topical Anesthetics Topical corticosteroids can suppress skin reactivity; therefore, discontinue use at the skin test site for 2 to 3 weeks before skin testing. Avoid use of topical local anesthetics at skin test sites as they can suppress flare responses. 2
7.3Tricyclic Antidepressants Tricyclic antidepressants can have potent antihistamine effects that can affect skin testing. If tricyclic medication has been recently discontinued, allow 7 to 14 days before initiating skin testing. 2
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. There are no human or animal data to establish the presence or absence of Non-Standardized Allergenic Extracts-associated risks during pregnancy.
8.2Lactation Risk Summary It is not known whether Non-Standardized Allergenic Extracts are present in human milk. Data are not available to assess the effects of these extracts on the breastfed child or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Non-Standardized Allergenic Extracts and any potential adverse effects on the breastfed child from the extracts or from the underlying maternal condition.
8.4Pediatric Use For use of these products in children younger than 5 years of age, consideration should be given to the patient’s ability to comply and cooperate with allergen immunotherapy and the potential for difficulty in communicating with the child regarding systemic reactions. 1
8.5Geriatric Use Data are not available to determine if subjects 65 years of age and older respond differently to allergen immunotherapy than younger subjects..
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The skin test reaction results from interaction of the introduced allergen and allergen-specific IgE antibodies bound to mast cells, leading to mast cell degranulation and release of histamine, tryptase and other mediators, which results in the formation of the wheal and flare. The precise mechanisms of action of allergen immunotherapy are not known. Immunologic responses to immunotherapy include changes in allergen-specific IgE levels, allergen-specific IgG levels, and regulatory T cell responses.
1
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1How Supplied Non-Standardized Allergenic Extracts and mixes may be supplied as aqueous stock concentrates of up to 1:10 weight/volume or 40,000 PNU/milliliter for intradermal and subcutaneous testing. The extracts may also be supplied as 50% glycerin stock concentrates of up to 1:20 weight/volume for use in percutaneous skin testing and subcutaneous immunotherapy. Non-Standardized Allergenic Extracts are labeled in weight/volume and/or PNU/milliliter and may be provided in 5, 10, and 50 milliliter vials.
Glycerinated extracts are also supplied in 5 milliliter dropper vials for prick or puncture testing. Non-Standardized Allergenic Extracts available are as follows: Pollens ‑ Grasses Bahia Grass, Paspalum notatum Brome, Smooth, Bromus inermis Canarygrass, Reed, Phalaris arundinacea Johnson Grass, Sorghum halepense Quack (Couch) Grass, Elymus repens Ryegrass, Giant Wild, Leymus condensatus Ryegrass, Italian, Lolium multiflorum Velvetgrass, Holcus lanatus Wheatgrass, Western, Pascopyrum smithii Pollens - Trees Acacia, Acacia dealbata Alder, Hazel, Alnus serrulata Alder, Red, Alnus rubra Alder, White, Alnus rhombifolia Ash, Arizona (Velvet), Fraxinus velutina Ash, Green, Fraxinus pennsylvanica Ash Mix (Equal parts Fraxinus pennsylvanica , Fraxinus americana ) Ash, Oregon, Fraxinus latifolia Ash, White, Fraxinus americana Aspen, Populus tremuloides Beech, American, Fagus grandifolia Birch, Black-Sweet, Betula lenta Birch, Mix (Equal parts Betula lenta , Betula nigra , Betula populifolia ) Birch, River, Betula nigra Birch, Spring, Betula occidentalis Birch, White, Betula populifolia Box Elder, Acer negundo Cedar, Mountain, Juniperus ashei Cedar, Red, Juniperus virginiana Cedar, Salt (Tamarisk), Tamarix gallica Central/Eastern 4 Tree Mix (Equal parts Ulmus americana , Acer negundo , Carya illinoinensis , Quercus virginiana ) Cottonwood, Arizona (Fremont), Populus fremontii Cottonwood, Black, Populus trichocarpa Cottonwood, Eastern, Populus deltoides Cottonwood, Western, Populus deltoides ssp. monilifera Cypress, Arizona, Callitropsis arizonica Cypress, Bald, Taxodium distichum Eastern Oak Mix (Equal parts Quercus velutina , Quercus rubra , Quercus alba ) Eastern 6 Tree Mix (Equal parts Fagus grandifolia , Populus deltoides , Quercus rubra , Betula nigra , Carya ovata , Fraxinus americana ) Eastern 7 Tree Mix (Equal parts Ulmus americana , Fagus grandifolia , Populus deltoides , Quercus rubra , Betula nigra , Carya ovata , Fraxinus americana ) Eastern 8 Tree Mix (Equal parts Ulmus americana , Fagus grandifolia , Populus deltoides , Quercus rubra , Betula nigra , Carya ovata , Fraxinus americana , Acer saccharum ) Eastern 10 Tree Mix (Equal parts Platanus occidentalis , Ulmus americana , Fagus grandifolia , Populus deltoides , Quercus rubra , Betula nigra , Carya ovata , Fraxinus americana , Acer saccharum , Liquidambar styraciflua ) Elm, American, Ulmus americana Elm, Cedar, Ulmus crassifolia Elm Mix (Equal parts Ulmus americana , Ulmus pumila ) Elm, Siberian, Ulmus pumila Eucalyptus, Bluegum, Eucalyptus globulus Hackberry, Celtis occidentalis Hazelnut, American, Corylus americana Hickory Mix (Equal parts Carya glabra , Carya ovata , Carya laciniosa , Carya tomentosa ) Hickory-Pecan Mix (Equal parts Carya illinoinensis , Carya ovata ) Hickory, Shagbark, Carya ovata Hickory, Shellbark, Carya laciniosa Hickory, White, Carya tomentosa Juniper Mix (Equal parts Juniperus monosperma , Juniperus scopulorum ) Juniper, Oneseed, Juniperus monosperma Juniper, Pinchot, Juniperus pinchotii Juniper, Rocky Mountain, Juniperus scopulorum Juniper, Utah, Juniperus osteosperma Juniper, Western, Juniperus occidentalis Locust Blossom, Black, Robinia pseudoacacia Mango Blossom, Mangifera indica Maple-Box Elder Mix (Equal parts Acer saccharum , Acer negundo ) 2 Maple Mix (Equal parts Acer rubrum , Acer saccharum ) 3 Maple Mix (Equal parts Acer rubrum , Acer saccharinum , Acer saccharum ) Maple, Red, Acer rubrum Mapl… [Excerpted — this section continues on DailyMed.]
📋 Description ▾
11 DESCRIPTION Non-Standardized Allergenic Extracts are sterile solutions used for percutaneous testing, intradermal testing, or subcutaneous immunotherapy. Aqueous extracts contain the soluble extractants of the source material in water for injection, 0.5% sodium chloride, 0.54% sodium bicarbonate, and 0.4% phenol. Glycerinated extracts contain the soluable extractants of the source material in water for injection and 50% glycerin, 0.25% sodium chloride, 0.27% sodium bicarbonate, and 0.2% phenol.
The pH of the extracts range from 6 to 9. Certain food extracts (Barley, Oat, Pineapple, Rye, Spinach, and Wheat), labeled “For Diagnostic Use Only”, contain 0.1% sodium formaldehyde sulfoxylate as an antioxidant. Source materials used in the manufacture of allergenic extracts are collected from natural sources or from laboratory cultures.
Non-Standardized Allergenic Extracts appear as clear and colorless to dark brown solutions that should be free of particulate matter. Extracts are labeled either as weight-to-volume based on the weight of the source material to the volume of the extracting fluid, or as PNU/milliliter with one PNU representing 0.00001 mg of protein nitrogen per milliliter.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES Specific immunotherapy with allergenic extracts is helpful in reducing symptoms associated with exposure to the offending allergens. A summary of effectiveness by the Panel on Review of Allergenic Extracts, an advisory committee to the U.S. Food and Drug Administration, has been published. 4
📚 References ▾
15 REFERENCES Cox LJ, Nelson H, Lockey R.Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol . 2011;127:(1)S1-55.
Bernstein IL, Li JT, Bernstein DI, et al.Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol . 2008;100:S1-148.
Greenberg MA, Kaufman CR, Gonzalez GE, et al. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol .
1986;77:865-870. Federal Register Proposed Rule: Biological Products: Implementation of Efficacy Review, Allergenic Extracts, Federal Register 1985;50: 3082-3288.
📄 Recent Major Changes ▾
RECENT MAJOR CHANGE RECENT MAJOR CHANGES Warning and Precautions, Anaphylaxis Following False Negative Food Allergen Skin Test Results (5.3) 01/2023
📄 Package Label / Principal Display Panel ▾
1027-2_House_Fly_20000-pnu 5004-4_American_Cockroach_20-wv
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |